GLP-1 Agonists Linked to Better Outcomes in HCC Patients With Diabetes
A target trial emulation study found that patients with diabetes and hepatocellular carcinoma (HCC) who initiated a GLP-1 receptor agonist had a longer time to cancer recurrence and improved overall survival compared with those who started a DPP-4 inhibitor. These findings suggest GLP-1 receptor agonists may offer additional benefits beyond glycemic control in this population, although confirmation in prospective randomized trials is needed. The study was published in the BMJ Hepatology by Yan-Jun X. and colleagues.
Patient-level EHR data were extracted from 36 tertiary-care hospitals located in China between 2014 and 2023, and clinical follow-up continued until October 1, 2025. Statistical analyses and data preparation were conducted carefully up to 2026. Patients who had been diagnosed with HCC, and also had T2D as a comorbidity condition, having successfully gone through a curative resection surgery with R0 resection of the liver were included in this analysis. In order to satisfy the inclusion criteria of a new user design, patients were required to start a new treatment course either with GLP-1RA or DPP-4i during the postoperative period from day 0 to day 90, and time zero corresponded to the start date of the qualifying prescription for both groups.
The primary analysis estimand used an intention-to-treat approach supplemented by per-protocol analysis for assessing adherence to treatment. Recurrence-free survival (RFS) was considered a primary clinical outcome, considering death due to causes unrelated to recurrence as a competing risk, whereas overall survival (OS) was a secondary endpoint.
Key findings:
- The primary multicenter registry database effectively selected a substantial baseline group of 42,855 patients with both HCC and T2D with liver resection surgery.
- After applying strict inclusion criteria, a final study group comprising 1,249 patients was identified, including 723 DPP-4i starters and 526 GLP-1RA starters.
- Postoperative outcome tracking was done for an extensive median follow-up period of 50.8 months.
- According to weighted intention-to-treat models, initiation of GLP-1RA was significantly associated with improved RFS with a cause-specific hazard ratio of 0.80 (95% CI, 0.67 to 0.96; p = 0.016).
- The results from the secondary analysis on survival revealed that GLP-1RA use was significantly associated with enhanced OS with a hazard ratio of 0.58 (95% CI, 0.47 to 0.71; p < 0.001).
Overall, postoperative GLP-1RA commencement was related to late recurrence and better survival rate than DPP-4i commencement; further studies should confirm this. The significant multi-center database data provide a necessary empirical basis for the field of metabolic oncology, demonstrating that structural treatment of metabolic diseases may influence the progression of primary liver cancer.
Reference:
Xiang Y- J, Liu Z- H, Feng J- K, et al. Gut Epub ahead of print: [please include Day Month Year]. doi:10.1136/ gutjnl-2026-338462
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.